PRAC
EMA review confirms risks of Abbvie and Biogen’s Zinbryta outweigh benefits
May 21, 2018Research and Development, Sales and Marketing EMA, Europe, European Commission, PRAC, multiple sclerosis, pharma, zinbryta
The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the …
EMA concludes HPV vaccines do not cause CRPS or POTS
November 9, 2015Sales and Marketing EMA, HPV, HPV vaccine, PRAC, complex regional pain syndrome, drug safety, postural orthostatic tachycardia syndrome
The European Medicines Agency says there is no evidence from a detailed scientific review of reports linking complex regional pain …
EMA keeps Ariad cancer drug on the market
October 13, 2014Sales and Marketing Ariad, CML, EMA, PRAC, iclusig, leukaemia, ponatinib
The EMA has recommended Ariad’s leukaemia drug Iclusig (ponatinib) should continue to be used under its current indication despite ongoing …
EMA starts contraceptive safety review
January 30, 2013Manufacturing and Production, Sales and Marketing EMA, PRAC, VTE, contraception
Europe’s health regulator is to examine the safety of newer forms of contraceptive pills following concerns over potential health risks …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
